Living Cell reports positive results of interim diabetes trial

In the study four insulin dependent patients have received DiabeCell implants with no remarkable adverse events. Two of the patients have completed six months observation and maintained significant prolonged clinical benefit. Early results from the trial of DiabeCell at the lowest dose believed to produce measurable outcomes, have demonstrated that DiabeCell was functional at six months, and that implantation significantly reduced the need for additional administration of insulin more than the anticipated maximum of 25%.

Bob Elliott, medical director of Living Cell, said: “These remarkable clinical outcomes have exceeded our expectations. We expect that higher doses of DiabeCell will support greater reductions in the insulin needs of patients.”